The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
Open accessAbstract
Despite progress in leukemia therapy, most children who experience relapse have a dismal prognosis. New, effective approaches are needed. We conducted a phase 1 study of a novel nucleoside analog, clofarabine, in pediatric patients with refractory and relapsed leukemia. Clofarabine was infused intravenously over 1 hour each day for 5 days. Six dose levels, between 11.25 and 70 mg/m2 per day for 5 days, were studied in 25 patients. A modified 3 + 3 phase 1 design was followed with 30% dose escalation until the dose-limiting toxicity (DLT) was defined. The maximum tolerated dose (MTD) was 52 mg/m2 per day for 5 days. At the end of infusion at MTD, clofarabine triphosphate levels in leukemia blasts varied between 6 μM and 19 μM, which resulted in complete and sustained inhibition of DNA synthesis. The DLT was reversible hepatotoxicity and skin rash at 70 mg/m2 per day for 5 days. Twenty-five patients were treated. Five patients achieved complete remission (CR), and 3 achieved partial remission (PR), for an overall response rate of 32%. Clofarabine is well tolerated and shows significant antileukemic activity in heavily pretreated children. Multicenter phase 2 trials in pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gandhi, V, Estey, E., Keating, M. J., & Plunkett, W. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.116 · Cited by 331
Self-citationChildren's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995
Gaynon, P., Trigg, M., Heerema, N., Sensel, M., Sather, H., Hammond, G., & Bleyer, W. (2000) · Leukemia · doi:10.1038/sj.leu.2401939 · Cited by 319
Kantarjian, H., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Giles, F., Faderl, S., O'Brien, S., Jeha, S., et al. (2003) · Blood · doi:10.1182/blood-2003-03-0925 · Cited by 314
Self-citationCancer chemotherapy and biological response modifiers annual
Pinedo, H. M., Longo, D. L., & Chabner, B. A. (1987) · Elsevier eBooks · Cited by 269
Parker, W. B., Shaddix, S. C., Chang, C., White, E. L., Rose, L. M., Brockman, R. W., Shortnacy, A. T., Montgomery, J. A. J., Secrist, J. A. I., & Bennett, L. L. (1991) · PubMed · Cited by 207
Yamauchi, T., Nowak, B. J., Keating, M. J., & Plunkett, W. K. (2001) · PubMed · Cited by 192
Self-citationKantarjian, H. M., Gandhi, V., Kozuch, P., Faderl, S., Giles, F., Cortes, J., O’Brien, S., Ibrahim, N., Khuri, F., Du, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.031 · Cited by 192
Self-citationGandhi, V, Estey, E., Keating, M., Chucrallah, A., & Plunkett, W. (1996) · Blood · doi:10.1182/blood.v87.1.256.256 · Cited by 162
Self-citationXie, K. C., & Plunkett, W. K. (1996) · PubMed · Cited by 133
Self-citationSEER update of incidence and trends in pediatric malignancies: Acute lymphoblastic leukemia
McNeil, D. E., Coté, T. R., Clegg, L. X., & Mauer, A. M. (2002) · Medical and Pediatric Oncology · doi:10.1002/mpo.10161 · Cited by 110
Cited by
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Topp, M. S., Gökbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3247 · Cited by 658
How I treat relapsed childhood acute lymphoblastic leukemia
Locatelli, F., Schrappe, M., Bernardo, M. E., & Rutella, S. (2012) · Blood · doi:10.1182/blood-2012-02-265884 · Cited by 314
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Metadata
- Authors
- Jeha, S., Gandhi, V., Chan, K. W., McDonald, L., Ramirez, I., Madden, R., Rytting, M., Brandt, M., Keating, M., Plunkett, W., & Kantarjian, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-02-01
- Volume
- 103
- Issue
- 3
- Pages
- 784-789
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2163334163
- Cited by
- 256
- References
- 15
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. https://app.cochat.ai/papers/10.1182/blood-2003-06-2122
- The paper
- Jeha, S., Gandhi, V., Chan, K. W., McDonald, L., Ramirez, I., Madden, R., Rytting, M., Brandt, M., Keating, M., Plunkett, W., & Kantarjian, H. (2004). Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. https://doi.org/10.1182/blood-2003-06-2122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
